Company Filing History:
3 out of 70 
1 out of 137 
1 out of 113 
Years Active: 2020-2024
Title: Eisaku Kondo: Innovator in Cancer Research
Introduction
Eisaku Kondo is a prominent inventor based in Niigata, Japan, known for his significant contributions to cancer research. With a total of three patents to his name, Kondo has focused on developing innovative solutions to combat cancer metastasis and inflammatory diseases.
Latest Patents
Kondo's latest patents include the "Anti-S100A8/A9 antibody and use thereof." This invention provides a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that acts on inflammatory diseases. The composition contains an antibody or an antibody fragment that has antigen-binding activity for the S100A8/A9 heterodimer. This invention blocks the interaction between S100A8/A9 and its receptors, thereby strongly suppressing cancer metastasis both in vitro and in vivo, or alleviating inflammation. Another notable patent is the "Peptide and use therefor," which describes a peptide composed of a specific amino acid sequence that accumulates in cancer cells or tissues within the digestive system.
Career Highlights
Eisaku Kondo has worked at prestigious institutions such as Niigata University and Okayama University. His research has significantly advanced the understanding of cancer biology and therapeutic approaches.
Collaborations
Kondo has collaborated with notable colleagues, including Ken Saito and Masakiyo Sakaguchi, to further his research endeavors.
Conclusion
Eisaku Kondo's innovative work in cancer research exemplifies the impact of scientific inquiry on medical advancements. His patents reflect a commitment to developing effective treatments for cancer and inflammatory diseases.